<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00028665</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU1499</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CWRU1499</secondary_id>
    <secondary_id>CWRU-030040</secondary_id>
    <secondary_id>NCI-G01-2040</secondary_id>
    <nct_id>NCT00028665</nct_id>
  </id_info>
  <brief_title>Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Randomized Phase II Trial of B-Lymphocyte Purging of Autologous Peripheral Blood Progenitor Cells in Patients With B-Cell Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill&#xD;
      them or deliver cancer-killing substances to them without harming normal cells. Drugs used in&#xD;
      chemotherapy use different ways to stop cancer cells from dividing so they stop growing or&#xD;
      die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to&#xD;
      give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known if&#xD;
      combining rituximab with cyclophosphamide is more effective than cyclophosphamide alone in&#xD;
      stimulating peripheral stem cells for transplantation.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well giving cyclophosphamide with or&#xD;
      without rituximab followed by chemotherapy and peripheral stem cell transplantation works in&#xD;
      treating patients with recurrent non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the effects of mobilization therapy with or without rituximab on hematopoietic&#xD;
           stem cells, B and T lymphocytes, and natural killer cells in patients with advanced or&#xD;
           recurrent B-cell non-Hodgkin's lymphoma.&#xD;
&#xD;
        -  Compare the effects of B-lymphocyte purging using concurrent rituximab and mobilization&#xD;
           therapy vs a CD34+ cell enrichment device on hematopoietic stem cells, B and T&#xD;
           lymphocytes, and natural killer cells in the peripheral blood stem cell (PBSC)&#xD;
           infusates.&#xD;
&#xD;
        -  Compare the effect of these purging regimens on tumor cell content of PBSC infusates.&#xD;
&#xD;
        -  Compare the effects of these regimens on myeloid and lymphoid engraftment after&#xD;
           high-dose chemotherapy and autologous PBSC infusion in these patients.&#xD;
&#xD;
        -  Compare post-transplantation infection complications in patients treated with these&#xD;
           regimens.&#xD;
&#xD;
        -  Compare the response and relapse-free survival of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive mobilization therapy comprising rituximab IV over 2-5 hours on&#xD;
           days 1, 8, and 15 and cyclophosphamide IV over 3-6 hours on day 16. Beginning 36-48&#xD;
           hours after the completion of cyclophosphamide, patients receive filgrastim (G-CSF)&#xD;
           subcutaneously (SC) daily until blood counts recover. Patients then undergo peripheral&#xD;
           blood stem cell (PBSC) collection.&#xD;
&#xD;
      After completion of PBSC collection, patients receive high-dose chemotherapy comprising&#xD;
      carmustine IV on days -7 to -3 and etoposide IV and cisplatin IV for 3 days during days -7 to&#xD;
      -3. Patients may undergo involved-field radiotherapy to active or previously bulky (more than&#xD;
      5 cm) tumors daily for 7-10 days.&#xD;
&#xD;
      Patients receive unmanipulated PBSCs on day 0. Patients receive G-CSF SC daily beginning 4&#xD;
      hours after completion of PBSC infusion and continuing until neutrophil engraftment.&#xD;
&#xD;
        -  Arm II: Patients receive mobilization therapy comprising cyclophosphamide and G-CSF and&#xD;
           high-dose chemotherapy comprising carmustine, etoposide, and cisplatin as in arm I.&#xD;
           Patients may also undergo involved-field radiotherapy as in arm I. Patients receive CD34&#xD;
           cell-enriched PBSC on day 0 followed by G-CSF as in arm I.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 71 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total CD34 cells</measure>
    <time_frame>measured at baseline, at time of harvests, days 42 and 90 after the transplant, and 6 and 12 months after the transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T and B lymphocyte counts</measure>
    <time_frame>measured at baseline, at time of harvests, days 42 and 90 after the transplant, and 6 and 12 months after the transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease response</measure>
    <time_frame>measured at 4 weeks after the transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Engraftment</measure>
    <time_frame>measured at days 42 and 90 after the transplant, and 6 and 12 months after the transplant</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm I: with rituximab IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II: without rituximab IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Beginning 36-48 hours after the completion of cyclophosphamide, patients receive filgrastim (G-CSF) subcutaneously (SC) daily until blood counts recover. Patients receive G-CSF SC daily beginning 4 hours after completion of PBSC infusion and continuing until neutrophil engraftment.</description>
    <arm_group_label>Arm I: with rituximab IV</arm_group_label>
    <arm_group_label>Arm II: without rituximab IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>rituximab IV over 2-5 hours on days 1, 8, and 15</description>
    <arm_group_label>Arm I: with rituximab IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
    <description>After completion of PBSC collection, patients receive high-dose chemotherapy comprising carmustine IV on days -7 to -3</description>
    <arm_group_label>Arm I: with rituximab IV</arm_group_label>
    <arm_group_label>Arm II: without rituximab IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>After completion of PBSC collection, cisplatin IV for 3 days during days -7 to -3.</description>
    <arm_group_label>Arm I: with rituximab IV</arm_group_label>
    <arm_group_label>Arm II: without rituximab IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>cyclophosphamide IV over 3-6 hours on day 16.</description>
    <arm_group_label>Arm I: with rituximab IV</arm_group_label>
    <arm_group_label>Arm II: without rituximab IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>After completion of PBSC collection, etoposide IV for 3 days during days -7 to -3.</description>
    <arm_group_label>Arm I: with rituximab IV</arm_group_label>
    <arm_group_label>Arm II: without rituximab IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
    <description>Patients then undergo peripheral blood stem cell (PBSC) collection.</description>
    <arm_group_label>Arm I: with rituximab IV</arm_group_label>
    <arm_group_label>Arm II: without rituximab IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Arm I: Patients receive unmanipulated PBSCs on day 0. Arm II: Patients receive CD34 cell-enriched PBSC on day 0.</description>
    <arm_group_label>Arm I: with rituximab IV</arm_group_label>
    <arm_group_label>Arm II: without rituximab IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Patients may undergo involved-field radiotherapy to active or previously bulky (more than 5 cm) tumors daily for 7-10 days.</description>
    <arm_group_label>Arm I: with rituximab IV</arm_group_label>
    <arm_group_label>Arm II: without rituximab IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed B-cell non-Hodgkin's lymphoma (NHL)&#xD;
&#xD;
               -  Indolent or aggressive histology&#xD;
&#xD;
               -  No small lymphocytic lymphoma, Burkitt's lymphoma, or small lymphocytic&#xD;
                  non-Burkitt's lymphoma&#xD;
&#xD;
          -  CD20-positive and/or CD19-positive by immunohistochemistry or flow cytometry&#xD;
&#xD;
          -  Second or greater remission allowed&#xD;
&#xD;
               -  Partial remission, relapse, or refractory disease must have measurable tumor&#xD;
&#xD;
          -  Eligible for high-dose therapy followed by autologous peripheral blood stem cell&#xD;
             transplantation&#xD;
&#xD;
          -  No CNS involvement by lymphoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  12 to 65&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,200/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No renal dysfunction&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  LVEF at least 40%&#xD;
&#xD;
          -  No cardiac dysfunction&#xD;
&#xD;
          -  No myocardial infarction within the past 3 months&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  FEV_1 greater than 60%&#xD;
&#xD;
          -  DLCO at least 60% of predicted&#xD;
&#xD;
          -  No pulmonary dysfunction&#xD;
&#xD;
          -  No asthma&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No significant organ dysfunction&#xD;
&#xD;
          -  No severe comorbid condition&#xD;
&#xD;
          -  No uncontrolled diabetes&#xD;
&#xD;
          -  No severe or active infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Chemotherapy&#xD;
&#xD;
          -  No prior immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior high-dose chemotherapy with or without peripheral blood stem cell&#xD;
             transplantation&#xD;
&#xD;
          -  No more than 3 prior chemotherapy regimens for NHL&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy and recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Prior radiotherapy allowed&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omer N. Koc, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-7284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>January 4, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 9, 2010</last_update_submitted>
  <last_update_submitted_qc>June 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Omer Koc, MD</name_title>
    <organization>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

